Dose Requirement and Prolactin Elevation of Antipsychotics in Male and Female Patients with Schizophrenia or Related Psychoses

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2001 Apr 25

PMID 11318766

Citations 16

Authors

K I Melkersson

A L Hulting

A J Rane

Affiliations

Soon will be listed here.

Abstract

Aims: The aim of this study was to investigate the prolactin (PRL) secretion and the growth hormone (GH)-insulin-like growth factor I (IGF-I) axis in relation to gender and side-effects and dose of antipsychotic drugs during long-term treatment.

Methods: Forty-seven patients (21 men and 26 women), diagnosed with schizophrenia or related psychoses according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria and treated with different classical antipsychotics, were studied. Prolactin, GH and IGF-I were measured, as well as the serum concentration of the antipsychotics. In addition, body mass index (BMI) was calculated.

Results: The median daily, as well as the median body weight, adjusted daily dose of antipsychotic drugs was twofold higher in male compared with female patients. Antipsychotic-induced hyperprolactinaemia was more frequent and occurred at a lower daily dose of antipsychotics in women. Irrespective of sex, more than half of the patients had elevated BMI. Two patients had a slight increment in IGF-I levels, whereas the GH concentration, as assessed on a single occasion, was normal in all patients.

Conclusions: Patients on long-term antipsychotic therapy, with doses adjusted according to therapeutic efficiency, exhibited hyperprolactinaemia and elevated BMI, but no obvious influence on the GH-IGF-I axis. Furthermore, it appeared that the males required twice the dose of antipsychotic compared with females.

Citing Articles

Practical solutions for including sex as a biological variable (SABV) in preclinical neuropsychopharmacological research.

Dalla C, Jaric I, Pavlidi P, Hodes G, Kokras N, Bespalov A J Neurosci Methods. 2023; 401:110003.

PMID: 37918446 PMC: 10842858. DOI: 10.1016/j.jneumeth.2023.110003.

Effectiveness and safety of blonanserin in young and middle-aged female patients with schizophrenia: data from a post-marketing surveillance.

Bo Q, Wang X, Liu X, Sang H, Xun Z, Zhang R BMC Psychiatry. 2023; 23(1):115.

PMID: 36810039 PMC: 9945355. DOI: 10.1186/s12888-023-04598-y.

Meta-analysis of peripheral insulin-like growth factor 1 levels in schizophrenia.

Pejcic A, Jankovic S, Janjic V, Djordjic M, Milosavljevic J, Milosavljevic M Brain Behav. 2022; 13(1):e2819.

PMID: 36448977 PMC: 9847627. DOI: 10.1002/brb3.2819.

Treatments for Social Interaction Impairment in Animal Models of Schizophrenia: A Critical Review and Meta-analysis.

Hazani R, Lavidor M, Weller A Schizophr Bull. 2022; 48(6):1179-1193.

PMID: 35925025 PMC: 9673263. DOI: 10.1093/schbul/sbac093.

Romanescu M, Buda V, Lombrea A, Andor M, Ledeti I, Suciu M J Pers Med. 2022; 12(6).

PMID: 35743692 PMC: 9224918. DOI: 10.3390/jpm12060907.

References

Beumont P, Harris G, Carr P, Friesen H, KOLAKOWSKA T, MACKINNON P . Some endocrine effects of phenothiazines: a preliminary report. J Psychosom Res. 1972; 16(4):297-304. DOI: 10.1016/0022-3999(72)90013-x. View

Stanton J . Weight gain associated with neuroleptic medication: a review. Schizophr Bull. 1995; 21(3):463-72. DOI: 10.1093/schbul/21.3.463. View

Yonkers K, Kando J, Cole J, Blumenthal S . Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am J Psychiatry. 1992; 149(5):587-95. DOI: 10.1176/ajp.149.5.587. View

Brady K . Weight gain associated with psychotropic drugs. South Med J. 1989; 82(5):611-7. DOI: 10.1097/00007611-198905000-00017. View

Goldstein J . Gender differences in the course of schizophrenia. Am J Psychiatry. 1988; 145(6):684-9. DOI: 10.1176/ajp.145.6.684. View

Franks S . Regulation of prolactin secretion by oestrogens: physiological and pathological significance. Clin Sci (Lond). 1983; 65(5):457-62. DOI: 10.1042/cs0650457. View

Kebabian J, Calne D . Multiple receptors for dopamine. Nature. 1979; 277(5692):93-6. DOI: 10.1038/277093a0. View

Bernstein J . Psychotropic drug induced weight gain: mechanisms and management. Clin Neuropharmacol. 1988; 11 Suppl 1:S194-206. View

Yasui N, Tybring G, Otani K, Mihara K, Suzuki A, Svensson J . Effects of thioridazine, an inhibitor of CYP2D6, on the steady-state plasma concentrations of the enantiomers of mianserin and its active metabolite, desmethylmianserin, in depressed Japanese patients. Pharmacogenetics. 1997; 7(5):369-74. DOI: 10.1097/00008571-199710000-00005. View

10.

Gruen P, SACHAR E, Langer G, Altman N, Leifer M, Frantz A . Prolactin responses to neuroleptics in normal and schizophrenic subjects. Arch Gen Psychiatry. 1978; 35(1):108-16. DOI: 10.1001/archpsyc.1978.01770250110011. View

11.

Whalley L, CHRISTIE J, Brown S, Arbuthnott G . Schneider's first-rank symptoms of schizophrenia. An association with increased growth hormone response to apomorphine. Arch Gen Psychiatry. 1984; 41(11):1040-3. DOI: 10.1001/archpsyc.1983.01790220030005. View

12.

Melkersson K, Hulting A, Hall K . Hormonal evaluation in schizophrenic patients treated with neuroleptics. Neuro Endocrinol Lett. 2001; 20(3-4):199-204. View

13.

Meltzer H, Fang V . The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry. 1976; 33(3):279-86. DOI: 10.1001/archpsyc.1976.01770030003001. View

14.

Bang P, Eriksson U, Sara V, Wivall I, Hall K . Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. Acta Endocrinol (Copenh). 1991; 124(6):620-9. DOI: 10.1530/acta.0.1240620. View

15.

Meltzer H, KOLAKOWSKA T, Fang V, Fogg L, Robertson A, Lewine R . Growth hormone and prolactin response to apomorphine in schizophrenia and the major affective disorders. Relation to duration of illness and depressive symptoms. Arch Gen Psychiatry. 1984; 41(5):512-9. DOI: 10.1001/archpsyc.1984.01790160098013. View

16.

Chouinard G, Annable L, Steinberg S . A controlled clinical trial of fluspirilene, a long-acting injectable neuroleptic, in schizophrenic patients with acute exacerbation. J Clin Psychopharmacol. 1986; 6(1):21-6. View

17.

Sodergard R, Backstrom T, Shanbhag V, Carstensen H . Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem. 1982; 16(6):801-10. DOI: 10.1016/0022-4731(82)90038-3. View

18.

Eggert Hansen C, Rosted Christensen T, Elley J, Bolvig Hansen L, Kragh-Sorensen P, Larsen N . Clinical pharmacokinetic studies of perphenazine. Br J Clin Pharmacol. 1976; 3(5):915-23. PMC: 1428936. DOI: 10.1111/j.1365-2125.1976.tb00647.x. View

19.

Ghadirian A, Chouinard G, Annable L . Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J Nerv Ment Dis. 1982; 170(8):463-7. DOI: 10.1097/00005053-198208000-00004. View

20.

Rosen T, Bosaeus I, Tolli J, Lindstedt G, Bengtsson B . Increased body fat mass and decreased extracellular fluid volume in adults with growth hormone deficiency. Clin Endocrinol (Oxf). 1993; 38(1):63-71. DOI: 10.1111/j.1365-2265.1993.tb00974.x. View